1. Kaposi M: Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syphil 4:265, 1872
2. Giraldo G, Beth E, Haguenau F: Herpes-type virus particles in tissue culture of Kaposi's sarcoma from different geographic regions. J Natl Cancer Inst 49:1509, 1972
3. Beral V et al: Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection? Lancet 335:123, 1990
4. Chang Y et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865, 1994
5. Dourmishev LA et al: Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 67:175, 2003
6. Ganem D: KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. J Clin Invest 120:939, 2010
7. Russo JJ et al: Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 93:14862, 1996
8. Neipel F, Albrecht JC, Fleckenstein B: Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: Determinants of its pathogenicity? J Virol 71:4187, 1997
9. Damania B: Oncogenic gamma-herpesviruses: Comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol 2:656, 2004
10. Cathomas G: Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus. Herpes 10:72, 2003
11. Bais C et al: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391:86, 1998
12. Guo HG et al: Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J Virol 77:2631, 2003
13. Radkov SA, Kellam P, Boshoff C: The latent nuclear antigen of Kaposi sarcomaassociated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 6:1121, 2000
14. Kaleeba JA, Berger EA: Kaposi's sarcoma-associated herpesvirus fusion-entry receptor: Cystine transporter xCT. Science 311:1921, 2006
15. Rappocciolo G et al: Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. J Virol 82:4793, 2008
16. Dukers NH, Rezza G: Human herpesvirus 8 epidemiology: What we do and do not know. AIDS 17:1717, 2003
17. de Sanjose S et al: Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis 199:1449, 2009
18. Pauk J et al: Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 343:1369, 2000
19. Cattani P et al: Human herpesvirus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus-seronegative patients from central and southern Italy, with and without Kaposi's sarcoma. J Clin Microbiol 37:1150, 1999
20. Engels EA et al: Risk of transfusion-associated transmission of human herpesvirus 8. J Natl Cancer Inst 91:1773, 1999
21. Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 332:1181, 1995
22. Huang YQ et al: Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 345:759, 1995
23. Sturzl M et al: Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 91:1725, 1999
24. Dupin N et al: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96:4546, 1999
25. Ablashi D et al: Seroprevalence of human herpesvirus-8 (HHV-8) in countries of southeast Asia compared to the USA,the Caribbean and Africa. Br J Cancer 81:893, 1999
26. Whitby D et al: Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst 90:395, 1998
27. Veugelers PJ et al: Is the human immunodeficiency virus related Kaposi's sarcoma epidemic coming to an end? Insights from the tricontinental seroconverter study. Epidemiology 6:382, 1995
28. Sullivan RJ et al: HIV/AIDS: Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 47:1209, 2008.
29. Cronin DM, Warnke RA: Castleman disease: An update on classification and the spectrum of associated lesions. Adv Anat Pathol 16:236, 2009
30. Chen KT: Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol 8:287, 1984
31. Weninger W et al: Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 79:243, 1999
32. Gessain A, Duprez R: Spindle cells and their role in Kaposi's sarcoma. Int J Biochem Cell Biol 37:2457, 2005
33. Wang HW et al: Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36:687, 2004
34. Hong YK et al: Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 36:683, 2004
35. Henry M et al: Infection of circulating CD34+ cells by HHV-8 in patients with Kaposi's sarcoma. J Invest Dermatol 113:613, 1999
36. Rabkin CS et al: Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 336:988, 1997
37. Gil PS et al: Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc Natl Acad Sci U S A 95:8257, 1998
38. Judde JG et al: Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst 92:729, 2000
39. Duprez R et al: Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J Natl Cancer Inst 99:1086, 2007
40. Iscovich J et al: Classic Kaposi's sarcoma: Epidemiology and risk factors. Cancer 88:500, 2000
41. Brenner B et al: Classical Kaposi sarcoma: Prognostic factor analysis of 248 patients. Cancer 95:1982, 2002
42. Brambilla L et al: Mediterranean Kaposi's sarcoma. Associated pathology in a case study of 100 patients. G Ital Dermatol Venereol 123:477, 1988
43. Thijs A: L'angiosarcomatose de Kaposi au Congo belge et au Ruanda-Urundi. Ann Soc Belge Med Trop 37:295, 1957
44. Cook-Mozaffari P et al: The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer 78:1521, 1998
45. Taylor JF et al: Kaposi's sarcoma in Uganda: A clinico-pathological study. Int J Cancer 8:122, 1971
46. Templeton
AC, Bhana D: Prognosis in Kaposi's sarcoma.
J Natl Cancer Inst 55:1301, 1975
47. Dutz W, Stout AP: Kaposi's sarcoma in infants and children. Cancer 13:684, 1960
48. Harwood AR et al: Kaposi's sarcoma in recipients of renal transplants. Am J Med 67:759, 1979
49. Penn I: Kaposi's sarcoma in organ transplant recipients: Report of 20 cases. Transplantation 27:8, 1979
50. Penn I: Kaposi's sarcoma in organ transplant recipients. Transplantation 64:669, 1997
51. Greenfield DI et al: Kaposi's sarcoma in a patient with SLE. J Rheumatol 13:637, 1986
52. Halpern SM et al: Kaposi's sarcoma associated with immunosuppression for bullous pemphigoid. Br J Dermatol 37:140, 1997
53. Deschenes I et al: Kaposi's sarcoma following immune suppressive therapy for Wegener's granulomatosis. J Rheumatol 30:622, 2003
54. Barete S et al: Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipients. Arch Dermatol 136:1452, 2000
55. Centers for Disease Control: Kaposi's sarcoma and Pneumocystis carinii pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep 25:305, 1981
56. Hermans P et al: Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS 10:911, 1996
57. Renwick, N et al: Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 12:2481, 1998.
58. Ziegler JL, Katongole-Mbidde E: Kaposi's sarcoma in childhood: An analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer 65:200, 1996
59. Sasco AJ et al: The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One 5:e8621, 2010
60. Ficarra G et al: Kaposi's sarcoma of the oral cavity: A study of 134 patients with a review of the pathogenesis, epidemiology, clinical aspects, and treatment. Oral Surg Oral Med Oral Pathol 66:543, 1998
61. Tappero JW et al: Kaposi's sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 28:371, 1993
62. Gill PS et al: Pulmonary Kaposi's sarcoma: Clinical findings and results of therapy. Am J Med 87:57, 1989
63. Ioachim HL et al: Kaposi's sarcoma of internal organs: A multiparameter study of 86 cases. Cancer 75:1376, 1995
64. Ackerman AB: Subtle clues to diagnosis by conventional microscopy: The patch stage of Kaposi's sarcoma. Am J Dermatopathol 1:165, 1979
65. Cockerell CJ: Histopathological features of Kaposi's sarcoma in HIV infected individuals. Cancer Surv 10:73, 1991
66. Chor PJ, Santa Cruz DJ: Kaposi's sarcoma. A clinicopathologic review and differential diagnosis. J Cutan Pathol 19:6, 1992
67. Arav-Boger R: Treatment for Kaposi sarcoma herpesvirus: Great challenges with promising accomplishments. Virus Genes 38:195, 2009
68. Aoki Y, Tosato G: Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders. Expert Rev Anti Infect Ther 2:213, 2004
69. Hengge UR et al: Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2:281, 2002
70. Levine AM, Tulpule A: Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer 37:1288, 2001
71. Karrer S et al: Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am J Clin Dermatol 2:229, 2001
72. Walmsley S et al: Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical
alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group.
J Acquir Immune Defic Syndr 22:235, 1999
73. Housri N, Yarchoan R, Kaushal A: Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary? Cancer 116:273, 2010
74. Northfelt DW: Treatment of Kaposi's sarcoma. Current guidelines and future perspectives. Drugs 48:569, 1994
75. Mocroft A et al: The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: The EuroSIDA Study. Cancer 100:2644, 2004
76. Martin-Carbonero L et al: Pegylated liposomal
doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
AIDS 18:1737, 2004.
78. Stewart S et al: Randomized comparative trial of pegylated liposomal
doxorubicin versus
bleomycin and
vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal
Doxorubicin Study Group.
J Clin Oncol 16:683, 1998.
79. Northfelt DW et al: Pegylated-liposomal
doxorubicin versus
doxorubicin,
bleomycin, and
vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial.
J Clin Oncol 16:2445, 1998
80. Hengge UR et al: Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal
doxorubicin.
Eur J Cancer 37:878, 2001
81. Cooley T et al: A randomized, double-blind study of pegylated liposomal
doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
Oncologist 12:114, 2007
82. Cianfrocca M et al: Randomized trial of
paclitaxel versus pegylated liposomal
doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy.
Cancer 116(16):3969-3977, 2010
83. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV: Conversion to
sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma.
Transplantation 77:760, 2004
84. Stallone G et al:
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
N Engl J Med 352:1317, 2005
85. Safai B: Kaposi's sarcoma: An overview of classical and epidemic forms. In: AIDS, Modern Concepts and Therapeutic Challenges, edited by S Broder. New York, Marcel Dekker, 1987, p. 205
86. Di Lorenzo G: Update on classic Kaposi sarcoma therapy: New look at an old disease. Crit Rev Oncol Hematol 68:242, 2008
87. Kreuter A et al: Liposomal pegylated
doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
Cancer Invest 23:653, 2005
88. Beyeler M et al: The spectrum of mesenchymal skin neoplasms reflected by the new WHO classification. Onkologie 27:401, 2004
89. Jones EW: Malignant angidoendothelioma of the skin. Br J Dermatol 76:2, 1964
90. Holden CA, Spittle MF, Jones EW: Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 59:1046, 1987
91. Stewart FW, Treves N: Lymphangiosarcoma in postmastectomy lymphedema, Cancer 1:64, 1948
92. Goette DK, Detlefs RL: Postirradiation angiosarcoma. J Am Acad Dermatol 12:922, 1985
93. Breiteneder-Geleff S et al: Angiosarcoma express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385, 1999
94. Budd GT: Management of angiosarcoma. Curr Oncol Rep 4:515, 2002
95. Sasaki R et al: Angiosarcoma treated with radiotherapy: Impact of tumor type and size on outcome. Int J Radiat Oncol Biol Phys 52:1032, 2002
96. Wollina U et al: Angiosarcoma of the scalp: Treatment with liposomal
doxorubicin and radiotherapy.
J Cancer Res Clin Oncol 127:396, 2001
97. Abraham JA et al: Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 14:1953, 2007
98. Skubitz KM, Haddad PA:
Paclitaxel and pegylated-liposomal
doxorubicin are both active in angiosarcoma.
Cancer 104:361, 2005
99. Maki RG et al: Phase II study of
sorafenib in patients with metastatic or recurrent sarcomas.
J Clin Oncol 27:3133, 2009
100. Donghi D, Dummer R, Cozzio A: Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of
paclitaxel and
sorafenib.
Br J Dermatol 162:697, 2010